文献速递胸部肿瘤

在非小细胞肺癌中,PD-L1表达、肿瘤突变负荷和癌症基因突变比HLA I类基因型更能预测免疫检查点阻断的获益

PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non-Small Cell Lung Cancer.
PubMed 文献 · J Thorac Oncol · 2019-02-16

本研究在M. D. Anderson癌症中心200例接受ICB的晚期NSCLC患者中比较HLA I类杂合与纯合对PFS和OS的影响,并在CheckMate-012(n=75)和Chowell(n=371)队列中验证。三个队列均未发现HLA I类杂合性与PFS或OS显著相关,也无HLA I类超型/等位基因 consistently 与PFS或OS相关。可靶向驱动基因突变、STK11突变、PD-L1阴性表达和低TMB是三个队列中较差结局的预测因素。

要点

  • HLA I类基因型与晚期NSCLC接受ICB的PFS和OS均无显著相关性。
  • 可靶向驱动基因突变、STK11突变、PD-L1阴性表达和低TMB与较差结局相关。
  • HLA I类多样性对ICB获益的影响可能具有疾病特异性。

核心结论

  • HLA I类基因型与晚期NSCLC接受ICB的生存无关。
  • 肿瘤基因组和免疫标志物在预测NSCLC从ICB获益方面更有影响力。

研究设计与样本

  • 收集M. D. Anderson癌症中心接受ICB治疗的晚期NSCLC患者的HLA分型、基因组和临床数据。
  • 比较HLA I类杂合与纯合患者的PFS和OS,并分析HLA I类超型/等位基因。
  • 在CheckMate-012(n=75)和Chowell(n=371)两个已发表独立队列中验证。

主要发现

  • M. D. Anderson癌症中心队列(n=200)中HLA I类杂合性与PFS或OS无显著相关。
  • CheckMate-012队列(n=75)中HLA I类杂合性与PFS或OS无显著相关。
  • Chowell队列(n=371)中HLA I类杂合性与PFS或OS无显著相关。
  • 无HLA I类超型/等位基因被一致显示与PFS或OS相关。
  • 三个队列中较差结局的预测因素包括可靶向驱动基因突变、STK11突变、PD-L1阴性表达和低TMB。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Immune checkpoint blockade (ICB) has revolutionized the treatment of NSCLC, but only approximately 15% of patients achieve durable benefit. Understanding mechanisms of resistance to ICB is pivotal in developing more effective treatment strategies. Recent studies showed that human leukocyte antigen (HLA) class I heterozygosity might be important in mediating benefit from ICB. We aimed to investigate the impact of HLA class I genotype on outcomes of patients with NSCLC treated with ICB. METHODS: We collected HLA typing, genomic, and clinical data from patients with advanced NSCLC treated with ICB at M. D. Anderson Cancer Center. We compared HLA class I-heterozygous and HLA class I-homozygous patients for progression-free survival (PFS) and overall survival (OS). HLA I supertype/alleles were also analyzed. To validate our findings, we also analyzed two previously published independent cohorts of patients with NSCLC (the CheckMate-012 and Chowell cohorts). RESULTS: No significant correlations were observed for HLA class I zygosity and PFS or OS in the M. D. Anderson Cancer Center (n = 200), CheckMate-012 (n = 75), or Chowell (n = 371) cohorts. No HLA class I supertype/allele was consistently shown to be correlated with PFS or OS. Predictors of worse outcome across the three cohorts included presence of targetable driver mutation, serine/threonine kinase 11 gene (STK11) mutation, negative programmed death ligand 1 expression, and low tumor mutational burden. CONCLUSIONS: HLA class I genotype is not correlated with survival in advanced NSCLC treated with ICB. This suggests that the impact of HLA class I diversity may be disease specific and that tumor genomic and immune markers are more impactful in predicting benefit from ICB in NSCLC.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Negrao MV, Lam VK, Reuben A, et al. PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non-Small Cell Lung Cancer. J Thorac Oncol. 2019. PMID: 30780001. doi:10.1016/j.jtho.2019.02.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。